GraniteShares Advisors LLC Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

GraniteShares Advisors LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 21.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,870 shares of the biopharmaceutical company’s stock after acquiring an additional 693 shares during the period. GraniteShares Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $940,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ALNY. Allspring Global Investments Holdings LLC grew its stake in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 143 shares in the last quarter. Altitude Crest Partners Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth $30,000. V Square Quantitative Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $52,000. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $71,000. Finally, GAMMA Investing LLC lifted its stake in Alnylam Pharmaceuticals by 97.2% in the second quarter. GAMMA Investing LLC now owns 416 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 205 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded down $24.32 on Friday, hitting $262.69. The company had a trading volume of 3,762,558 shares, compared to its average volume of 864,553. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $287.55. The company has a 50-day moving average price of $255.96 and a 200-day moving average price of $187.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. The company’s revenue was up 107.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.21) earnings per share. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.82 EPS for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the transaction, the director now owns 136 shares in the company, valued at $30,013.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the transaction, the director now directly owns 136 shares in the company, valued at $30,013.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 103,148 shares of company stock valued at $25,658,824. Corporate insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. UBS Group boosted their price target on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a report on Friday, June 28th. HC Wainwright restated a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday. Leerink Partners lifted their price target on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a report on Tuesday, June 25th. Cantor Fitzgerald upped their price objective on Alnylam Pharmaceuticals from $150.00 to $220.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. Finally, JPMorgan Chase & Co. lifted their target price on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. Seven analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $278.59.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.